Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

Summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Timeline

Start

2019-06-10

Primary completion

2021-03-18

Completion

2021-03-18

Drugs

Indications